Can HRT Improve GLP1 Weight Loss After Menopause?
HRT and GLP1: An Emerging Weight-Loss Connection
Many women find that their bodies change in midlife in ways that diet and exercise no longer seem to control. Weight may shift toward the abdomen, clothing fits differently and strategies that once worked become less effective. With semaglutide medications such as Wegovy and Ozempic now so widely prescribed, women in menopause have also begun asking whether their hormones affect how well these medications work.
Emerging research suggests that women using HRT may experience a greater weight loss response to semaglutide, the active ingredient in Wegovy and Ozempic. The findings are intriguing, but they are early and observational. A careful look at what they do and do not show can help women plan their care with Oakland County functional medicine doctor Nishath Hakim, MD.
Why Menopause Can Complicate Weight Management
Midlife weight changes have several overlapping causes, and understanding them helps explain why a single solution rarely works for every woman. Aging itself gradually reduces muscle mass and slows metabolism, while lifestyle factors such as sleep, stress and activity levels often change during the same years. The menopause transition adds another layer, because declining estrogen is associated with a shift in fat storage toward the abdomen and with changes in insulin sensitivity.
It would be inaccurate, however, to attribute every midlife change to estrogen alone. Aging and menopause-related factors both contribute, and their relative influence varies from one woman to another. HRT can relieve hot flashes and improve sleep, which may make healthy routines easier to maintain, but it is not considered a weight loss treatment on its own.
Researchers are now exploring whether reproductive stage and HRT use might also influence how women respond to GLP1 medications, which could eventually help physicians tailor treatment more precisely. Even so, menopause symptoms and excess weight are separate health concerns that each deserve their own careful assessment, even when they occur at the same time.
What Earlier HRT and GLP1 Research Found
The first study to draw attention to this question was published in 2024 in the journal Menopause. Researchers at the Mayo Clinic reviewed medical records of postmenopausal women who received semaglutide for weight loss, comparing those who used hormone therapy with those who did not.
After 12 months, women using hormone therapy had lost an average of about 16 percent of their total body weight, compared with about 12 percent among women not using hormones. They were also more likely to reach certain weight loss milestones, such as losing at least 10 percent of their starting weight. Weight loss was similar between the groups in the first months of treatment, with the difference becoming more apparent over time.
The study was small, involving 16 women on hormone therapy and 90 women not using it, and it was a retrospective review rather than a randomized trial testing the addition of HRT. Women who chose hormone therapy may have differed in other ways that influenced their results. The findings support further investigation, but they do not guarantee additional weight loss for any individual patient, and the authors themselves called for larger studies.
New HRT Findings Expand the Evidence
Larger findings were announced by The Menopause Society in October 2026 and are being presented at its 2026 Annual Meeting. Led by researchers at the Mayo Clinic, this retrospective cohort study included nearly 2,400 women taking semaglutide and nearly 1,500 taking tirzepatide, the active ingredient in Zepbound and Mounjaro. All of the women were older than 45 and had a body mass index above 27.
Among women taking semaglutide, HRT use was associated with significantly greater weight loss that was sustained over time. Because this study was far larger than the 2024 review, it adds considerable weight to the earlier observation, although its design still has important limits. Among women taking tirzepatide, those using hormone therapy initially lost more weight, but the final difference between groups was not statistically significant.
These are conference findings reported by the society and have not yet appeared as a full peer-reviewed publication. Like the earlier study, they are observational, so they cannot establish that hormone therapy was responsible for the additional weight loss. The study’s lead author emphasized that the results need confirmation in well-designed prospective trials.
What This Could Mean for Wegovy
Because both studies involved semaglutide, many women taking or considering Wegovy or Ozempic will be interested in these results. Researchers have proposed that estrogen and GLP1 signaling may interact in ways that enhance appetite regulation and metabolic effects, a theory supported by laboratory and animal research. This remains a proposed explanation rather than an established mechanism in women. Researchers also noted that the stronger association with semaglutide than with tirzepatide is not yet understood and will require further study.
The studies cannot establish whether HRT itself caused the greater weight loss, and they do not prove that any specific combination of hormone therapy and Wegovy produces better results. Women who used hormone therapy may have differed in health, symptom control, sleep quality or other factors that influenced their weight.
It is also important to understand that HRT is not required for GLP1 treatment to be effective, and many women lose significant weight with GLP1 medications alone. The Menopause Society has emphasized that weight loss is not an indication for menopausal hormone therapy, so HRT should not be prescribed solely to amplify weight loss.
Coordinating HRT at Prosperity Health
Because menopause symptoms and weight concerns often occur together, a consultation at Prosperity Health considers both in a coordinated way. Dr. Hakim reviews symptoms such as hot flashes, sleep disruption and mood changes, along with weight history, metabolic health, medications and personal goals. Laboratory testing may also be used to evaluate blood sugar, cholesterol, thyroid function and other factors that influence both hormones and weight, so that every recommendation is based on a complete picture of each woman’s health.
Depending on her individual circumstances, a woman may be an appropriate candidate for HRT, for GLP1 treatment such as Wegovy, for both or for neither. When both are appropriate, each is prescribed for its own medical reason and monitored carefully, with attention to side effects, laboratory results and progress over time. Women who are not candidates for HRT, or who would rather avoid hormones, can still benefit fully from a GLP1 medication such as Wegovy or Ozempic when it is medically appropriate.
Sustainable results also depend on the fundamentals. Adequate protein, balanced meals, consistent movement and resistance exercise help preserve muscle during weight loss and support long-term metabolic health. Oakland County functional medicine doctor Nishath Hakim, MD helps patients set achievable goals and adjust their plans as their bodies and needs change.
GLP1 & HRT Doctor | Oakland County
If menopause symptoms and weight changes are both affecting your life, you do not have to sort through the research alone. A personalized evaluation can clarify whether HRT, GLP1 medications like Wegovy and Ozempic, or a combination may fit your health needs.
Schedule an appointment with Oakland County functional medicine doctor Nishath Hakim, MD to build a personalized treatment plan for menopause and weight management. Each recommendation will be grounded in your symptoms, your health history and the latest research.
Oakland County GLP1 & HRT Doctor: 248-997-4242
Research:
